|
Market Closed -
Japan Exchange
02:30:00 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 6,353.00 JPY | +1.37% |
|
+5.55% | -22.93% |
| 09-22 | Chugai Pharma to Boost Capex by 50% to Expand In-House Production | MT |
| 08-21 | Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets | MT |
Company Valuation: Chugai Pharmaceutical Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,141,311 | 5,540,406 | 8,789,053 | 11,516,953 | 13,565,544 | 10,452,610 | - | - |
| Change | - | -9.78% | 58.64% | 31.04% | 17.79% | -22.95% | - | - |
| Enterprise Value (EV) 1 | 5,669,311 | 5,051,408 | 8,050,071 | 10,520,608 | 13,138,942 | 9,540,960 | 9,296,926 | 9,015,583 |
| Change | - | -10.9% | 59.36% | 30.69% | 24.89% | -27.38% | -2.56% | -3.03% |
| P/E | 20.3x | 14.8x | 27x | 29.7x | 31.3x | 20.7x | 18x | 16x |
| PBR | 5.17x | 3.89x | 5.41x | 6.06x | 6.7x | 4.66x | 4.06x | 3.55x |
| PEG | - | 0.6x | -2.1x | 1.6x | 2.6x | 1.3x | 1.2x | 1.3x |
| Capitalization / Revenue | 6.14x | 4.4x | 7.91x | 9.84x | 10.8x | 7.56x | 6.86x | 6.31x |
| EV / Revenue | 5.67x | 4.01x | 7.24x | 8.99x | 10.4x | 6.9x | 6.1x | 5.44x |
| EV / EBITDA | 12.3x | 8.93x | 17.1x | 18.3x | 20.4x | 13.1x | 11.2x | 9.74x |
| EV / EBIT | 13.4x | 9.47x | 18.3x | 19.4x | 21.9x | 13.8x | 11.7x | 10.1x |
| EV / FCF | 35.3x | 27.7x | 21.6x | 47.8x | 71x | 21.6x | 18.1x | 15.1x |
| FCF Yield | 2.83% | 3.61% | 4.63% | 2.09% | 1.41% | 4.63% | 5.51% | 6.63% |
| Dividend per Share 2 | 76 | 78 | 80 | 98 | 272 | 134.8 | 153.9 | 172.4 |
| Rate of return | 2.03% | 2.32% | 1.5% | 1.4% | 3.3% | 2.12% | 2.42% | 2.71% |
| EPS 2 | 184.3 | 227.6 | 197.8 | 235.4 | 263.7 | 306.5 | 352 | 395.9 |
| Distribution rate | 41.2% | 34.3% | 40.4% | 41.6% | 103% | 44% | 43.7% | 43.6% |
| Net sales 1 | 999,800 | 1,259,946 | 1,111,367 | 1,170,611 | 1,257,900 | 1,382,366 | 1,523,414 | 1,656,657 |
| EBITDA 1 | 459,100 | 565,376 | 470,914 | 573,667 | 643,900 | 728,672 | 828,691 | 925,719 |
| EBIT 1 | 421,900 | 533,309 | 439,174 | 542,002 | 598,800 | 691,826 | 796,630 | 893,907 |
| Net income 1 | 303,000 | 374,429 | 325,472 | 387,317 | 434,000 | 504,386 | 579,242 | 651,441 |
| Net Debt 1 | -472,000 | -488,998 | -738,982 | -996,345 | -426,602 | -911,650 | -1,155,684 | -1,437,026 |
| Reference price 2 | 3,735.00 | 3,368.00 | 5,342.00 | 6,999.00 | 8,243.00 | 6,353.00 | 6,353.00 | 6,353.00 |
| Nbr of stocks (in thousands) | 1,644,260 | 1,645,014 | 1,645,274 | 1,645,514 | 1,645,705 | 1,645,303 | - | - |
| Announcement Date | 2/3/22 | 2/2/23 | 2/1/24 | 1/30/25 | 1/29/26 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.73x | 6.9x | 13.09x | 2.12% | 66.2B | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 28.22x | 6.94x | 17.86x | 2.15% | 400.71B | |
| Weighted average by Cap. | 34.49x | 8.18x | 19.92x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4519 Stock
- Valuation Chugai Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
